Background: The gene therapeutic Cal-1 comprises the anti-HIV agents: (i) sh5, a short hairpin RNA to CCR5 that down-regulates CCR5 expression and (ii) maC46 (C46), a peptide that inhibits viral fusion with the cell membrane. These constructs were assessed for inhibition of viral replication and selective cell expansion in a number of settings. Methods: HIV replication, selective outgrowth and cell surface viral binding were analysed with a single cycle infection assay of six pseudotyped HIV strains and a static and longitudinal passaging of MOLT4/CCR5 cells with HIV. Pronase digestion of surface virus and fluorescence microscopy assessed interactions between HIV virions and transduced cells. Results: Cal-1 reduced CCR5 expression in periph...
International audienceThe chemokine receptor CCR5 has been the focus of intensive studies since its ...
Background: Gene therapy holds considerable promise for the functional cure of HIV-1 infection and, ...
HIV entry into target cells requires the interaction of the HIV envelope glycoprotein (Env) with a p...
HIV currently infects 35 million people worldwide and antiretroviral treatments are expensive, lifel...
Treatment with RNAi against HIV-1 transcripts efficiently inhibits viral replication but induces sel...
The introduction of combination antiretroviral therapy (cART) in 1996 has significantly reduced HIV ...
. These authors contributed equally to this work. CCR5, a coreceptor for HIV-1 entry, is a major tar...
BACKGROUND: Despite the remarkable success of highly active antiretroviral therapy (HAART) in loweri...
Gene transfer has therapeutic potential for treating HIV-1 infection by generating cells that are re...
Gene transfer has therapeutic potential for treating HIV-1 infection by generating cells that are re...
BackgroundThe use of shRNAs to downregulate the expression of specific genes is now relatively routi...
Gene transfer has therapeutic potential for treating HIV-1 infection by generating cells that are re...
This is a copy of an article published in Human Gene Therapy Methods © [2014 [copyright Mary Ann Lie...
Human immunodeficiency virus type 1 (HIV-1) infection of target cells requires CD4 and a co-receptor...
<p>A and B) Effect of soluble recombinant CCR5-T4L or CCL5 on macrophages using cell-cell fusion ass...
International audienceThe chemokine receptor CCR5 has been the focus of intensive studies since its ...
Background: Gene therapy holds considerable promise for the functional cure of HIV-1 infection and, ...
HIV entry into target cells requires the interaction of the HIV envelope glycoprotein (Env) with a p...
HIV currently infects 35 million people worldwide and antiretroviral treatments are expensive, lifel...
Treatment with RNAi against HIV-1 transcripts efficiently inhibits viral replication but induces sel...
The introduction of combination antiretroviral therapy (cART) in 1996 has significantly reduced HIV ...
. These authors contributed equally to this work. CCR5, a coreceptor for HIV-1 entry, is a major tar...
BACKGROUND: Despite the remarkable success of highly active antiretroviral therapy (HAART) in loweri...
Gene transfer has therapeutic potential for treating HIV-1 infection by generating cells that are re...
Gene transfer has therapeutic potential for treating HIV-1 infection by generating cells that are re...
BackgroundThe use of shRNAs to downregulate the expression of specific genes is now relatively routi...
Gene transfer has therapeutic potential for treating HIV-1 infection by generating cells that are re...
This is a copy of an article published in Human Gene Therapy Methods © [2014 [copyright Mary Ann Lie...
Human immunodeficiency virus type 1 (HIV-1) infection of target cells requires CD4 and a co-receptor...
<p>A and B) Effect of soluble recombinant CCR5-T4L or CCL5 on macrophages using cell-cell fusion ass...
International audienceThe chemokine receptor CCR5 has been the focus of intensive studies since its ...
Background: Gene therapy holds considerable promise for the functional cure of HIV-1 infection and, ...
HIV entry into target cells requires the interaction of the HIV envelope glycoprotein (Env) with a p...